1. Fig. 1.  Drug survival curve for patients treated with a fully human anti‐TNF moAb (D2E7; n=61) or MTX (n=137). Percentage of patients still on therapy on the y‐axis. Time in weeks on the x‐axis.
From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis
Rheumatology (Oxford). 2002;41(4): doi: /rheumatology/
Rheumatology (Oxford) | © British Society for Rheumatology

2. Fig. 2.  Clinical response in patients treated with human anti‐TNF moAb (D2E7; n=61) or MTX (n=137) monotherapy. Percentages of good and moderate responders (open and solid symbols, respectively) according to the EULAR criteria. Time in weeks on the x‐axis. MTX and D2E7 are represented as triangles and boxes, respectively. ▪, □, anti‐TNF therapy; ▵, MTX.
From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis
Rheumatology (Oxford). 2002;41(4): doi: /rheumatology/
Rheumatology (Oxford) | © British Society for Rheumatology

3. Fig. 3.  Course of the DAS during 48 weeks of therapy with anti‐TNF (n=61) or MTX (n=137) monotherapy. DAS on the y‐axis. Time in weeks on the x‐axis.
From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis
Rheumatology (Oxford). 2002;41(4): doi: /rheumatology/
Rheumatology (Oxford) | © British Society for Rheumatology